Brii Biosciences Limited (BRIBF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $93.8M is the value of all shares combined. Beta 1.23: the stock has moved about 23% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBrii Biosciences Limited (BRIBF) trades at $0.13. Brii Biosciences Limited is a biotechnology company focused on developing innovative therapies for infectious diseases and central nervous system disorders. Market cap: $93.8M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for BRIBF: BRIBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BRIBF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
BRIBF: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Brii Biosciences Limited (BRIBF) Healthcare & Pipeline Overview
Brii Biosciences Limited specializes in developing therapeutic solutions for infectious diseases and CNS disorders, with a robust pipeline targeting significant health challenges in China and beyond.
What Is the Investment Thesis for BRIBF?
Brii Biosciences Limited presents a unique investment thesis driven by its innovative pipeline and focus on significant unmet medical needs. The company's ongoing clinical trials for HIV and Hepatitis B, particularly the promising BRII-835, which has completed Phase 2 trials, could lead to substantial market opportunities as these therapies progress towards commercialization. Additionally, the development of therapies for COVID-19 and CNS disorders like postpartum depression further diversifies its portfolio and enhances growth potential. With a current market capitalization of $93.8M and a gross margin of 84.8%, Brii is positioned to capitalize on the growing demand for effective treatments in these areas. However, the company faces challenges, including a high profit margin of -1124.4% and the risks associated with being traded on the OTC Other tier, which may impact liquidity and investor confidence. Monitoring the outcomes of its clinical trials and regulatory approvals will be critical for assessing Brii's future performance.
Based on FMP financials and quantitative analysis
BRIBF Key Highlights
Market capitalization of $93.8M reflects the company's emerging status in the biotechnology sector.
- Profit margin of -1124.4% indicates significant operational challenges, necessitating close monitoring.
- Gross margin of 84.8% demonstrates strong potential for profitability upon successful product commercialization.
- Free cash flow of -$0.27 billion highlights the need for ongoing funding to support clinical development.
- Beta of 1.23 suggests higher volatility compared to the broader market, indicating potential investment risk.
Who Are BRIBF's Competitors?
BRIBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| GILD Gilead Sciences, Inc. | $144.81 | -0.58% | $180B | 635-pillar |
| BMY Bristol-Myers Squibb Company | $63.34 | -0.64% | $129B | 905-pillar |
| MRNA Moderna, Inc. | $136.62 | +0.74% | $54.2B | 305-pillar |
| ICCC ImmuCell Corporation | $9.91 | +0.05% | $89.7M | 775-pillar |
| RLYB Rallybio Corporation | $16.75 | -1.30% | $88.9M | 825-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.74 | -0.38% | $194M | 785-pillar |
| NAGE Niagen Bioscience Inc | $3.04 | -0.49% | $242M | 665-pillar |
| QTTB Q32 Bio Inc. | $10.93 | +1.96% | $325M | 685-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BRIBF's Key Strengths?
Innovative pipeline targeting significant health challenges.
- Strong focus on the Chinese market with high unmet needs.
- Experienced leadership team with a track record in biotechnology.
What Are BRIBF's Weaknesses?
High operational costs leading to negative profit margins.
- Limited market presence compared to larger competitors.
- Dependency on successful clinical trial outcomes for future growth.
What Could Drive BRIBF Stock Higher?
Results from Phase I clinical trials for BRII-778 and BRII-732 in HIV patients.
- Phase 2 study evaluations for BRII-179 and BRII-835 in Hepatitis B.
- Development of Amubarvimab/romlusevimab combination therapy for COVID-19.
What Are the Key Risks for BRIBF?
Negative return on equity (-8.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- High operational costs leading to negative profit margins.
- Regulatory challenges that may delay clinical trial progress.
- Intense competition from established biotechnology firms.
What Are the Growth Opportunities for BRIBF?
- Growth opportunity 1: The global market for HIV therapeutics is projected to reach $30 billion by 2026, driven by increasing prevalence and demand for effective treatments. Brii's BRII-778 and BRII-732, currently in Phase I trials, could capture significant market share if they demonstrate efficacy and safety, positioning the company favorably within this lucrative segment.
- Growth opportunity 2: Hepatitis B remains a critical health issue, particularly in Asia, with an estimated market size of $5 billion for HBV treatments by 2027. Brii's ongoing Phase 2 studies for BRII-179 and BRII-835 could lead to innovative solutions that address this unmet need, enhancing the company's growth trajectory and market presence.
- Brii's development of BRII-296 for PPD positions the company to tap into this expanding market and provide much-needed therapies for affected individuals.
- Growth opportunity 4: The COVID-19 pandemic has underscored the necessity for effective antiviral treatments, with the global antiviral market anticipated to exceed $50 billion by 2026. Brii's Amubarvimab/romlusevimab combination therapy could play a pivotal role in addressing this ongoing health crisis, potentially leading to substantial revenue streams.
- Growth opportunity 5: The increasing prevalence of multi-drug resistant infections has created a pressing need for innovative anti-infective therapies. Brii's portfolio, including candidates like BRII-636 and BRII-672, targets these critical health challenges, positioning the company to capitalize on a market projected to reach $20 billion by 2028.
What Opportunities Does BRIBF Have?
- Growing demand for effective treatments in infectious diseases.
- Potential for strategic partnerships to enhance research capabilities.
- Expansion into international markets as therapies progress.
What Threats Does BRIBF Face?
- Intense competition from established biotechnology firms.
- Regulatory challenges and potential delays in clinical trials.
- Market volatility impacting investor confidence and funding.
What Are BRIBF's Competitive Advantages?
- Strong pipeline of innovative therapies addressing unmet medical needs.
- Focus on the large and growing Chinese healthcare market.
- Expertise in developing treatments for complex diseases like HIV and Hepatitis B.
What Does BRIBF Do?
Brii Biosciences Limited, founded in 2017 and based in Beijing, China, is committed to creating advanced therapeutic solutions for infectious diseases and disorders of the central nervous system. The company emerged from a vision to address unmet medical needs in these critical areas, leveraging innovative research and development strategies. Brii's pipeline includes several promising candidates, such as BRII-778 and BRII-732, which are currently in Phase I clinical trials targeting HIV patients. For Hepatitis B (HBV), Brii is evaluating BRII-179 and BRII-835 in a combined Phase 2 study, with BRII-179 also positioned as a recombinant protein-based immunotherapeutic in Phase 1b/2a. Notably, BRII-835 has successfully completed Phase 2 trials for chronic HBV patients, showcasing the company's commitment to advancing treatment options. Additionally, Brii is developing the Amubarvimab/romlusevimab combination therapy for COVID-19, reflecting its adaptive approach to emerging health crises. In the central nervous system domain, BRII-296 targets postpartum depression (PPD), while BRII-297 addresses various depressive disorders. The company's anti-infective portfolio includes BRII-636, BRII-672, and BRII-693, which are designed to combat multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections, alongside BRII-658 for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections. With a dedicated workforce of 98 employees, Brii is strategically positioned to leverage the large Chinese market and expand its influence in the global biotechnology landscape.
What Products and Services Does BRIBF Offer?
- Develop therapeutic solutions for infectious diseases.
- Focus on central nervous system disorders and mental health treatments.
- Advance a diverse pipeline of drug candidates through various clinical trial phases.
- Target significant health issues prevalent in China and globally.
- Conduct research and development to innovate treatment options.
- Collaborate with healthcare professionals and regulatory bodies to ensure compliance.
How Does BRIBF Make Money?
- Generate revenue through the commercialization of successful drug candidates.
- Engage in partnerships and collaborations for research and development.
- Leverage intellectual property rights to protect innovations and secure funding.
- Attract investment to support ongoing clinical trials and operational expenses.
What Industry Does BRIBF Operate In?
The biotechnology industry is experiencing rapid growth, driven by increasing demand for innovative therapies and advancements in genetic research. With a global market projected to reach $2.4 trillion by 2028, companies like Brii Biosciences Limited are well-positioned to capitalize on this trend, particularly in the realm of infectious diseases and CNS disorders. The competitive landscape includes various players focused on similar therapeutic areas, but Brii's targeted approach to the Chinese market, which has a significant burden of infectious diseases, provides a strategic advantage. The ongoing need for effective treatments in these areas underscores the relevance of Brii's pipeline.
Who Are BRIBF's Key Customers?
- Healthcare providers seeking effective treatment options for patients.
- Pharmaceutical partners interested in collaboration for drug development.
- Patients suffering from infectious diseases and CNS disorders.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 254 days ago
- ● No analyst coverage
- ● Reported in CNY, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 46 |
| 2026-08-26 | 46 |
| 2026-08-29 | 46 |
| 2026-09-01 | 46 |
| 2026-09-04 | 46 |
| 2026-09-07 | 46 |
| 2026-09-10 | 46 |
What changed?
The score has stayed at 46.
Over the same 18 days the stock moved +0.0%.
Brii Biosciences Limited Financial Trajectory
Brii Biosciences Limited (BRIBF) reported $2.6M in revenue for Q4 FY2025, reflecting 3450.5% growth compared to the prior quarter. The company recorded a net loss of $21.3M, with diluted EPS of $-0.01. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare.
Company Profile
Brii Biosciences Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Beijing, CN. The company is led by CEO Zhi Hong. BRIBF has traded publicly since 2022.
How Brii Biosciences Limited Is Valued
Brii Biosciences Limited carries a market capitalization of $93.8M, placing it in the micro-cap category.
Key Financial Metrics
Return on equity for Brii Biosciences Limited stands at -8.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -9.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -52.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 60.73 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -36.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Brii Biosciences Limited's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 10.53 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
Brii Biosciences Limited has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 29.5% above estimates on average.
Forward Outlook
Wall Street analysts project Brii Biosciences Limited revenue of about $310.3M for fiscal 2026, with EPS near $-0.45.
BRIBF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative pipeline targeting significant health challenges.
- Strong focus on the Chinese market with high unmet needs.
- Experienced leadership team with a track record in biotechnology.
- Upcoming: Results from Phase I clinical trials for BRII-778 and BRII-732 in HIV patients.
Bear Case
- High operational costs leading to negative profit margins.
- Limited market presence compared to larger competitors.
- Dependency on successful clinical trial outcomes for future growth.
- Potential: High operational costs leading to negative profit margins.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 FY2025 | $3M | -$21M | -$0.01 |
| Q2 FY2025 | $74,142.345 | -$11M | -$0.01 |
| Q4 FY2024 | $2M | -$17M | -$0.02 |
Q4 FY2025 · filed 31 Dec 2025 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from CNY at today's rate
BRIBF Latest News
-
Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results
Yahoo! Finance: BRIBF News · Aug 20, 2026
BRIBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BRIBF.
Price Targets
Wall Street price target analysis for BRIBF.
BRIBF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BRIBF; grades run from A+ (80-100) to F (below 30).
Leadership: Zhi Hong
CEO
Zhi Hong has extensive experience in the biotechnology sector, having held various leadership roles in both research and corporate strategy. With a strong academic background in life sciences, Zhi has been instrumental in driving Brii Biosciences' vision to develop innovative therapies for unmet medical needs. Prior to joining Brii, he worked with several leading pharmaceutical companies, where he honed his expertise in drug development and commercialization.
Track Record: Under Zhi Hong's leadership, Brii Biosciences has successfully advanced multiple drug candidates through various stages of clinical trials, positioning the company for future growth. His strategic focus on the Chinese market has enabled Brii to leverage significant opportunities in addressing infectious diseases and CNS disorders.
BRIBF OTC Market Information
The OTC Other tier includes companies that do not meet the listing requirements for major exchanges like NYSE or NASDAQ. This tier often has less stringent reporting and regulatory requirements, which can lead to less transparency and higher risks for investors. Companies in this tier may also experience lower trading volumes and liquidity.
- OTC Tier: OTC Other
- Limited liquidity can lead to increased volatility in stock price.
- Potential lack of transparency in financial reporting.
- Regulatory risks associated with being traded on the OTC market.
- Verify the company's clinical trial progress and results.
- Review financial statements for insights into operational health.
- Assess the competitive landscape and market positioning.
- Monitor regulatory developments and approval timelines.
- Evaluate management's track record and strategic vision.
- Established in 2017 with a focus on significant health challenges.
- Diverse pipeline of drug candidates in various clinical stages.
- Experienced leadership team with a background in biotechnology.
Brii Biosciences Limited Healthcare Stock: Key Questions Answered
Is BRIBF a good stock?
Stock Expert AI does not rate BRIBF buy, sell or hold. Brii Biosciences Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What is Brii Biosciences Limited's drug pipeline status?
Brii Biosciences Limited has several candidates in various stages of clinical trials. Notably, BRII-778 and BRII-732 are in Phase I trials for HIV, while BRII-179 and BRII-835 are being evaluated in a combined Phase 2 study for Hepatitis B. Additionally, the company is developing therapies for COVID-19 and CNS disorders, showcasing a robust and diverse pipeline.
What are the key factors to evaluate for BRIBF?
Evaluate BRIBF on fundamentals, analyst consensus, and risk factors. Free cash flow of -$0.27 billion highlights the need for ongoing funding to support clinical development. Not financial advice.
How frequently does BRIBF data refresh on this page?
BRIBF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BRIBF's recent stock price performance?
Brii Biosciences Limited (BRIBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline targeting significant health challenges. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BRIBF overvalued or undervalued right now?
Brii Biosciences Limited (BRIBF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of BRIBF?
Yes, most major brokerages offer fractional shares of Brii Biosciences Limited (BRIBF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BRIBF's earnings and financial reports?
Brii Biosciences Limited (BRIBF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for BRIBF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The financial data is based on the latest available information and may be subject to change as new reports are released.